BioWorld

July 18, 2005

Chiron's Pulminiq 'Approvable,' But Flu Vaccine Trouble Arises

After to a split advisory committee vote last month on Chiron Corp.'s Pulminiq, the FDA issued an approvable letter but asked for another study to confirm efficacy of the lung transplant drug. (BioWorld Today) Read More

Adherex Could Get $220M In Cancer Deal With GSK

BrainCells' Neurogenesis Work Brings In $17.7M In First Round

To Keep Biodefense Issues In Focus, Be 'Involved Politically'

Trading Heavy As Momenta's Stock Price Jumps Once Again

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...

MicroRNAs in circulating extracellular vesicles as IPF biomarkers

BioWorld Science

MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...